We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Joint Corp. (JYNT) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, The Joint Corp. (JYNT - Free Report) closed at $17.50, marking a +0.34% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.12%. At the same time, the Dow lost 0.04%, and the tech-heavy Nasdaq gained 0.32%.
Prior to today's trading, shares of the company had gained 9.2% over the past month. This has outpaced the Medical sector's gain of 3.52% and the S&P 500's gain of 3.31% in that time.
Wall Street will be looking for positivity from JYNT as it approaches its next earnings report date. Meanwhile, our latest consensus estimate is calling for revenue of $11.08 million, up 46.6% from the prior-year quarter.
JYNT's full-year Zacks Consensus Estimates are calling for earnings of $0.21 per share and revenue of $46.31 million. These results would represent year-over-year changes of +425% and +45.67%, respectively.
Investors should also note any recent changes to analyst estimates for JYNT. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 8.15% lower within the past month. JYNT is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note JYNT's current valuation metrics, including its Forward P/E ratio of 84.39. For comparison, its industry has an average Forward P/E of 14.89, which means JYNT is trading at a premium to the group.
Meanwhile, JYNT's PEG ratio is currently 8.44. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - HMOs stocks are, on average, holding a PEG ratio of 1.03 based on yesterday's closing prices.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 16, which puts it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Joint Corp. (JYNT) Gains As Market Dips: What You Should Know
In the latest trading session, The Joint Corp. (JYNT - Free Report) closed at $17.50, marking a +0.34% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.12%. At the same time, the Dow lost 0.04%, and the tech-heavy Nasdaq gained 0.32%.
Prior to today's trading, shares of the company had gained 9.2% over the past month. This has outpaced the Medical sector's gain of 3.52% and the S&P 500's gain of 3.31% in that time.
Wall Street will be looking for positivity from JYNT as it approaches its next earnings report date. Meanwhile, our latest consensus estimate is calling for revenue of $11.08 million, up 46.6% from the prior-year quarter.
JYNT's full-year Zacks Consensus Estimates are calling for earnings of $0.21 per share and revenue of $46.31 million. These results would represent year-over-year changes of +425% and +45.67%, respectively.
Investors should also note any recent changes to analyst estimates for JYNT. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 8.15% lower within the past month. JYNT is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note JYNT's current valuation metrics, including its Forward P/E ratio of 84.39. For comparison, its industry has an average Forward P/E of 14.89, which means JYNT is trading at a premium to the group.
Meanwhile, JYNT's PEG ratio is currently 8.44. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - HMOs stocks are, on average, holding a PEG ratio of 1.03 based on yesterday's closing prices.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 16, which puts it in the top 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.